Medpace Holdings, Inc. (MEDP) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Wait for pullback to $378.74. BUY gates pass at $421.87, but concentration risk — Customer: small biopharmaceutical companies (82.0%) and analyst target reached - limited upside remaining argue for a more patient entry. Engine's entry $378.74 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
Medpace is a full-service clinical CRO providing Phase I–IV drug development services to biotechnology, pharmaceutical, and medical device companies, with approximately 6,200 employees across 46 countries. Revenue comes from fixed-fee and variable clinical service contracts; 82%... Read more
Wait for pullback to $378.74. BUY gates pass at $421.87, but concentration risk — Customer: small biopharmaceutical companies (82.0%) and analyst target reached - limited upside remaining argue for a more patient entry. Engine's entry $378.74 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 53. Wide-moat business. Accumulate on weakness. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 61d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Medpace Holdings, Inc.
Material events (past 30 days)
- Apr 22, 2026 MEDIUM Item 5.02: Jesse Geiger, President, notified company of intent to resign effective May 31, 2026. No successor named.
Latest news
- MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class A — PR Newswire negative
- Medpace Holdings (MEDP) Reports Strong Q1 Earnings Amid Leadersh - GuruFocus — GuruFocus positive
- Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8% - StockStory — StockStory positive
- Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8% - Yahoo! Finance Canada — Yahoo! Finance Canada positive
- Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8% - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-21T00:01:23Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomersmall biopharmaceutical companies82%10-K Item 1A: '82% and 13% of our net revenue was derived from small biopharmaceutical companies and mid-sized biopharmaceutical companies, respectively'
- MEDIUMCustomertop-10 customers35%10-K Item 1A: 'we derive approximately 35.1% of our net revenue from our top ten customers'
Material Events(8-K, last 90d)
- 2026-04-22Item 5.02MEDIUMJesse Geiger, President, notified company of intent to resign effective May 31, 2026. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $378.74. BUY gates pass at $421.87, but concentration risk — Customer: small biopharmaceutical companies (82.0%) and analyst target reached - limited upside remaining argue for a more patient entry. Engine's entry $378.74 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 53. Wide-moat business. Accumulate on weakness. Target $426.45 (+1.1%), stop $355.45 (−18.7%), Setup A.R:R 2.8:1. Score 5.9/10, moderate confidence.
Take-profit target: $426.45 (+12.6% upside). Target $426.45 (+1.1%), stop $355.45 (−18.7%), Setup A.R:R 2.8:1. Stop-loss: $355.45.
Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining.
Medpace Holdings, Inc. trades at a P/E of 26.5 (forward 22.6). TrendMatrix value score: 4.4/10. Verdict: Buy (Wait for Entry).
20 analysts cover MEDP with a consensus score of 3.6/5. Average price target: $443.
What does Medpace Holdings, Inc. do?Medpace is a full-service clinical CRO providing Phase I–IV drug development services to biotechnology, pharmaceutical,...
Medpace is a full-service clinical CRO providing Phase I–IV drug development services to biotechnology, pharmaceutical, and medical device companies, with approximately 6,200 employees across 46 countries. Revenue comes from fixed-fee and variable clinical service contracts; 82% of net revenue derives from small biopharmaceutical companies and 13% from mid-sized biopharmaceutical companies.